Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and previously-treated nusinersen patients with SMA1Biogen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback